HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CI 949

antiallergic cpd; interleukin-1 and interleukin-2 antagonist

Also Known As:

5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H-indole-2-carboxamide, L-arginine salt; CI-949

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - CI 949: 6
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - CI 949: 6

Experts

1.	Liu, Yecai: 1 article (06/2009)
2.	Maloney, Susan A: 1 article (06/2009)
3.	Ortega, Luis S: 1 article (06/2009)
4.	Painter, John A: 1 article (06/2009)
5.	Weinberg, Michelle S: 1 article (06/2009)

Related Diseases

1.	Hypersensitivity (Allergy) 10/01/1993 - "Toxicity of CI-949, a novel anti-allergy agent." 01/01/1990 - "CI-949: a new, potential antiallergy compound inhibits antigen-induced allergic reactions in guinea-pigs in vitro and in vivo."
2.	Allergic Rhinitis 12/01/1990 - "Furthermore, the activity and potency of CI-949 in inhibiting release of histamine, leukotrienes, and thromboxane from both human basophils and mast cells suggest that the compound will be effective clinically for indications in which these mediators are implicated, including asthma and allergic rhinitis."
3.	Tuberculosis (Tuberculoses) 06/04/2009 - "From 1999 through 2005, a total of 26,075 smear-negative cases of tuberculosis (i.e., cases in which a chest radiograph was suggestive of active tuberculosis but sputum smears were negative for acid-fast bacilli on 3 consecutive days) and 22,716 cases of inactive tuberculosis (i.e., cases in which a chest radiograph was suggestive of tuberculosis that was no longer clinically active) were diagnosed by overseas medical screening of 2,714,223 U.S.-bound immigrants, representing prevalences of 961 cases per 100,000 persons (95% confidence interval [CI], 949 to 973) and 837 cases per 100,000 persons (95% CI, 826 to 848), respectively. "
4.	Neoplasms (Cancer) 11/01/1991 - "CI-949 treatment of female B6C3F1 mice increased pulmonary tumor burden at 100 mg/kg/day in the B16F10 melanoma model, with a no effect level of at least 50 mg/kg/day. "
5.	Melanoma (Melanoma, Malignant) 11/01/1991 - "Resistance to the bacterial pathogens Listeria monocytogenes and Streptococcus pneumoniae and the B16F10 melanoma cell line was used to evaluate the potential of CI-949 to affect immune function. " 11/01/1991 - "CI-949 treatment of female B6C3F1 mice increased pulmonary tumor burden at 100 mg/kg/day in the B16F10 melanoma model, with a no effect level of at least 50 mg/kg/day. "

Related Drugs and Biologics

1.	Leukotrienes
2.	Thromboxanes
3.	Histamine (Histamine Dihydrochloride)
4.	Antigens
5.	Acids